Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
SRK Capital Sean Kirkwood | “Solésence (SLSN), formerly Nanophase Technologies (NANX), manufactures zinc oxide, a crucial mineral for sunscreens that protects against both UVA and UVB rays. The company caught my attention during the first half of 2024 as an intriguing investment due to its stock price being under pressure despite its rapid growth and attractive product offering. This was due to manufacturing issues that squeezed profit margins and a lawsuit with a long-term customer. However, management's commentary suggested these problems were likely to be resolved favorably in the near term along with continued rapid growth and a potential uplisting to the Nasdaq. The company resolved the litigation favorably last April and continues to do business with the customer, removing an overhang on the stock price. Revenue for the first six months of this year have grown 53%, but the company is still struggling with lower margins due to one-time costs to onboard new large customers. In April, the company uplisted to the Nasdaq and was added to the Russell 2000 index in the most recent reconstitution, this has seemingly led to increased volume and momentum in the stock price. With the stock, at one point, up over 100% for the year and above my estimate of fair value, I chose to exit the majority of our position at favorable prices. BSD Analysis: Solésence looks like a small specialty-formulation business, where value is created through IP, formulation know-how, and sticky customer relationships rather than sheer scale. These companies win when they own a high-value niche—think performance ingredients or advanced formulations where customers pay for outcomes, not commodities. The risk is that small operators can get squeezed by input-cost volatility and customer concentration. The upside is meaningful if the company is moving up the value chain into higher-margin, proprietary products with repeat demand. Investors should focus on gross margin trend, repeat customer concentration, and evidence of pricing power. If management can keep working capital tight and expand higher-margin offerings, operating leverage can appear quickly. This is a “small base, big operating leverage” setup—if it's real.” | BULL | Q2 2025 Aug 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
